Literature DB >> 2293549

Dose-dependent effects of hydralazine on microcirculatory function and hyperthermic response of murine FSall tumors.

J Kalmus1, P Okunieff, P Vaupel.   

Abstract

The effects of the vasodilator hydralazine (HYD) on microcirculatory function and hyperthermic response were studied in early generation isotransplants of a spontaneous C3Hf/Sed mouse fibrosarcoma (FSall). Red blood cell flux (RBC flux) in superficial tumor regions was assessed using laser Doppler flowmetry. A differential microcirculatory response was seen between tumor and normal skin after 0.25 micrograms/g i.p. HYD, the tumor showing a transient increase in flow and the skin remaining almost stable. At 1.0 micrograms/g i.p., the differential response continued, this time with a transient fall in tumor blood flow but again no change in skin flow. High dose hydralazine (10.0 micrograms/g i.p.) was associated with a dramatic and prolonged decrease in tumor blood flow but a lesser and only transient decline in skin flow. Identical doses of hydralazine were given 30 min prior to heat treatment (43.5 degrees C for 15, 30, or 60 min). Tumor growth was measured daily and compared to controls (HT without hydralazine). Hydralazine at 0.25 micrograms/g i.p. did not affect heat induced growth delay. At 1.0 micrograms/g i.p., it significantly increased growth delay upon heat exposures of 15 min, but not after 30 or 60 min HT. Hydralazine at 10 micrograms/g i.p. increased growth delay for all heat doses (P less than 0.05). Hydralazine alone had no influence on growth delay of sham-heated tumors. The results obtained clearly indicate that tumor and normal tissues have microcirculatory differences in the time-course, degree and/or direction of response after hydralazine, and that hydralazine has potential for increasing the response of tumor to HT.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2293549

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  10 in total

1.  Effect of nitro-L-arginine on blood flow, oxygenation and the activity of hypoxic cell cytotoxins in murine tumours.

Authors:  M R Horsman; D J Chaplin; S A Hill; S Arnold; D Collingridge; M Radacic; P J Wood; J Overgaard
Journal:  Br J Cancer Suppl       Date:  1996-07

2.  Effect of hydralazine in spontaneous tumours assessed by oxygen electrodes and 31P-magnetic resonance spectroscopy.

Authors:  M Nordsmark; R J Maxwell; P J Wood; I J Stratford; G E Adams; J Overgaard; M R Horsman
Journal:  Br J Cancer Suppl       Date:  1996-07

3.  Changes in energy metabolism and X-ray sensitivity in murine tumours by the nitric oxide donor SIN-1.

Authors:  P J Wood; J M Sansom; I J Stratford; G E Adams; C Szabo; C Thiemermann; J R Vane
Journal:  Br J Cancer Suppl       Date:  1996-07

4.  In vivo 31P nuclear magnetic resonance spectroscopy of experimental murine tumours and human tumour xenografts: effects of blood flow modification.

Authors:  J C Bremner; C J Counsell; G E Adams; I J Stratford; P J Wood; J F Dunn; G K Radda
Journal:  Br J Cancer       Date:  1991-11       Impact factor: 7.640

5.  The potential for prazosin and calcitonin gene-related peptide (CGRP) in causing hypoxia in tumours.

Authors:  I A Burney; R J Maxwell; J R Griffiths; S B Field
Journal:  Br J Cancer       Date:  1991-10       Impact factor: 7.640

6.  The influence of hydralazine on the vasculature, blood perfusion and chemosensitivity of MAC tumours.

Authors:  P K Quinn; M C Bibby; J A Cox; S M Crawford
Journal:  Br J Cancer       Date:  1992-08       Impact factor: 7.640

7.  31P-magnetic resonance spectroscopy and 2H-magnetic resonance imaging studies of a panel of early-generation transplanted murine tumour models.

Authors:  S P Robinson; A van den Boogaart; R J Maxwell; J R Griffiths; E Hamilton; J C Waterton
Journal:  Br J Cancer       Date:  1998-06       Impact factor: 7.640

8.  Direct evidence that hydralazine can induce hypoxia in both transplanted and spontaneous murine tumours.

Authors:  M R Horsman; M Nordsmark; M Høyer; J Overgaard
Journal:  Br J Cancer       Date:  1995-12       Impact factor: 7.640

9.  Inhibition of the regulation of intracellular pH: potential of 5-(N,N-hexamethylene) amiloride in tumour-selective therapy.

Authors:  J Luo; I F Tannock
Journal:  Br J Cancer       Date:  1994-10       Impact factor: 7.640

10.  Hydralazine augmented ultrasound hyperthermia for the treatment of hepatocellular carcinoma.

Authors:  Mrigendra B Karmacharya; Laith R Sultan; Stephen J Hunt; Chandra M Sehgal
Journal:  Sci Rep       Date:  2021-07-30       Impact factor: 4.996

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.